| Name | Olafertinib |
| Description | Olafertinib (RX-518) is a novel mutant-selective, irreversible, orally available EGFR inhibitor. It can overcome T790M-mediated resistance in NSCLC. |
| In vitro | CK-101 specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward WT EGFR. It selectively inhibits cell proliferation of cell lines expressing both the activating (HCC827, IC50 <15 nM) and resistance mutations (NCI-H1975, IC50 <5 nM). |
| In vivo | CK-101 significantly inhibits tumor growth in EGFR-mutated NSCLC tumor xenograft models, with no activity in the WT EGFR tumor xenograft model. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | H2O : Insoluble 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (7.54 mM), Sonication is recommended. DMSO : 120 mg/mL (226.17 mM), Sonication is recommended.
|
| Keywords | RX518 | RX 518 | Olafertinib | NSCLC | Inhibitor | inhibit | HER1 | ErbB-1 | Epidermal growth factor receptor | EGFR (T790M) | EGFR | CK101 | CK 101 |
| Inhibitors Related | (S)-Afatinib | Osimertinib | Lidocaine Hydrochloride hydrate | Lapatinib | Erlotinib hydrochloride | Erlotinib | Neratinib | Afatinib | Chalcone | Brigatinib | Genistein | Gefitinib |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Tyrosine Kinase Inhibitor Library | Kinase Inhibitor Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Immunology/Inflammation Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |